Orexigen Therapeutics (OREXQ) Stock Price, News & Analysis

Company Overview

Orexigen Therapeutics, Inc. is a biopharmaceutical company founded in 2002 and headquartered in La Jolla, California. The company was focused on the development and commercialization of pharmacological treatments for obesity and related metabolic disorders. During its operational period, Orexigen advanced multiple clinical programs designed to address the global rise in obesity and its associated health risks.

The company’s lead product, Contrave, is a fixed-dose combination of naltrexone and bupropion that was approved by the U.S. Food and Drug Administration in 2014 for chronic weight management in adults. Contrave works through a dual-mechanism of action targeting the central nervous system pathways involved in appetite regulation. Orexigen partnered with Takeda Pharmaceutical Company to commercialize Contrave in the United States and established additional licensing agreements for distribution in select international markets.

In October 2018, Orexigen Therapeutics filed for Chapter 11 bankruptcy protection, and its primary assets were subsequently acquired by Nalpropion Pharmaceuticals, which continues to develop and market Contrave under the name Mysimba in certain jurisdictions. The former Orexigen equity is now traded on the OTC market under the ticker OREXQ, representing residual interests in the company’s wind-down trust. While Orexigen no longer operates as an independent commercial entity, its work in obesity therapeutics laid groundwork for ongoing research into combination treatments for metabolic disease.

Key Stats

• Today's Range: $0.0027 to $0.0053
• 50-Day Range: $0.0053 to $0.0053
• 52-Week Range: $0.00 to $0.16
• Volume: 60,300 shs
• Average Volume: 80,439 shs
• Market Capitalization: $100.10 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OREXQ
• CIK: 1382911
• Web: www.orexigen.com
• Phone: 858-875-8600
• Fax: N/A
• Employees: 132
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $33.71 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,887,000
• Free Float: N/A
• Market Cap: $100.10 thousand
• Optionable: Not Optionable
• Beta: 4.98